drugset / Trial / NCT01844076
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
Establish the tolerability and safety of aimed dose of both quinacrine and capecitabine in combination to treat patients with advanced colorectal adenocarcinoma.
Timeline
- Start
- 2016-01-14
- Primary completion
- 2019-08-09
- Completion
- 2019-08-09
Outcome
Outcome not reported
Stopped: “The single Quinacrine manufacture facility in the US was shut down by the FDA”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Quinacrine | Small molecule | 100 mg | — |
| Subject | Quinacrine | Small molecule | 200 mg | — |